SWTX

SpringWorks Therapeutics, Inc. (SWTX) | Rumor.io

SpringWorks Therapeutics

SWTX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)56%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about SWTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% -0.01

Aug 16

SpringWorks Therapeutics, Inc. ($SWTX) is experiencing a surge in activity.
The company's stock price is likely to be affected by this development.
The exact nature of the activity is unclear, but it appears to be significant.

Generated by AI

Sentiment

Of the messages about SWTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	0% 0	69.96% -9.56
Bearish	—	100%	100% 0	30.04% +9.56

Bullish· Apr 28

SpringWorks Therapeutics, Inc. ($SWTX) has been acquired by Merck KGaA for $47 per share in cash, representing a significant premium for investors who held the stock.
The acquisition is expected to accelerate sustainable growth in Merck's healthcare business, and the deal is subject to customary closing conditions, including approval of SpringWorks' shareholders.
Despite the lower-than-expected buyout price, investors who held $SWTX for less than a year were still able to realize significant gains, with some reporting profits of up to 45%.

Bearish· Apr 28

The buyout price of $3.9B is significantly lower than the company's estimated value of $5-6B, leading to a disappointing return on investment.
The company's management is criticized for selling the company at a "fire sale price" and prioritizing their own compensation over retail investors' interests.
The buyout premium is considered low, especially considering the company's strong fundamentals, including FDA approvals, cash reserves, and valuable patents.

Generated by AI

Topics

Of the messages about SWTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	0%	0%	0.84%
Announcements	—	100%	70%	97.49%
Controversies	—	0%	0%	0%
Earnings	—	0%	30%	1.68%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	0%

Apr 28

Merck KGaA agreed to acquire SpringWorks Therapeutics for $47 per share in cash, representing an equity value of approximately $3.9 billion.
The acquisition is expected to be accretive to Merck KGaA's earnings per share in 2027 and will immediately contribute to Merck KGaA's revenues.
The deal is subject to customary closing conditions, including approval of SpringWorks' shareholders and receipt of required regulatory approvals, and is expected to close in the second half of 2025.

Generated by AI

Community

Of the messages about SWTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	88.16%
Newcomers	—	0%	0%	11.84%

Regulars· Apr 28

Merck KGaA agreed to acquire SpringWorks Therapeutics for $47 per share in cash, a deal with an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion).
The acquisition is expected to accelerate sustainable growth of Merck's healthcare business, and SpringWorks' CEO, Saqib Islam, stated that the deal creates significant value for shareholders and enables the company to leverage Merck's resources and expertise.
Some regular investors are disappointed with the buyout price, citing that SpringWorks would have reached $47 per share by itself after the FDA approval, and questioning the competence of SpringWorks' management in negotiating the deal.

Newcomers· Apr 28

The buyout price of $47 per share represents a 26% premium to the 20-day volume-weighted average price (VWAP) of $37.38.
Merck KGaA is acquiring SpringWorks Therapeutics for nearly $4 billion, with the purchase price of $47 per share in cash representing an equity value of approximately $3.9 billion.
The deal aims to accelerate the sustainable growth of Merck's healthcare business, with the two companies' medicines, Ogosiveo (nirogacestat) and Gomekli (mirdametinib), being highlighted as best-in-class therapies.

Generated by AI

Also Discussed

Investors talking about SWTX also mention

#	Name	Attention
1	BPMC - Blueprint Medicines Corporation	——
2	VRNA - Verona Pharma plc	——
3	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
4	APLS - Apellis Pharmaceuticals, Inc.	——
5	MRTX - Mirati Therapeutics, Inc.	——
6	Revolution Medicines, Inc.RVMD	0.01%-0.01
7	DAWN - Day One Biopharmaceuticals, Inc.	——
8	IDEAYA Biosciences Inc.IDYA	0%-0.01
9	Cytokinetics, IncorporatedCYTK	0.01%+0
10	PSTX - Poseida Therapeutics, Inc.	——